Advertisement
CVM vs MDGL
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Hold and MDGL is a Hold.
CVM's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for CVM moved out of overbought territory on October 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 22 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVM as a result. In 90 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CVM turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 41 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CVM broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +18.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVM advanced for three days, in 176 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 52 of 60 cases where CVM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. CVM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.729) is normal, around the industry mean (26.782). P/E Ratio (0.330) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MDGL in -4.16% downward trend, sliding for three consecutive days on October 13, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MDGL declined for three days, in 260 of 328 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDGL as a result. In 69 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for MDGL turned negative on September 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 29 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
MDGL moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDGL crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 57%.
The Aroon Indicator for MDGL entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 222 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.831) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (9.443) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
CVM | MDGL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 22 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 46 | 62 | |
P/E GROWTH RATING 1..100 | 37 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDGL's Valuation (66) in the Pharmaceuticals Other industry is in the same range as CVM (97) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CVM’s over the last 12 months.
MDGL's Profit vs Risk Rating (22) in the Pharmaceuticals Other industry is significantly better than the same rating for CVM (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than CVM’s over the last 12 months.
MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as CVM (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CVM’s over the last 12 months.
CVM's Price Growth Rating (46) in the Biotechnology industry is in the same range as MDGL (62) in the Pharmaceuticals Other industry. This means that CVM’s stock grew similarly to MDGL’s over the last 12 months.
CVM's P/E Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that CVM’s stock grew somewhat faster than MDGL’s over the last 12 months.
| CVM | MDGL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 77% |
| Advances ODDS (%) | 9 days ago 79% | 17 days ago 76% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CVM’s FA Score shows that 0 FA rating(s) are green while MDGL’s FA Score has 1 green FA rating(s).
- CVM’s FA Score: 0 green, 5 red.
- MDGL’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CVM’s TA Score shows that 3 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).
- CVM’s TA Score: 3 bullish, 5 bearish.
- MDGL’s TA Score: 4 bullish, 6 bearish.
Price Growth
CVM (@Biotechnology) experienced а -36.13% price change this week, while MDGL (@Biotechnology) price change was -8.93% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.49%. For the same industry, the average monthly price growth was -19.00%, and the average quarterly price growth was -19.88%.
Reported Earning Dates
CVM is expected to report earnings on Dec 23, 2026.
MDGL is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (-8.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement